Susceptibility of Pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis

Pharmacotherapy

Volumn 21, Issue 11, 2001, Pages 1320-1324

  Robinson, Robert J ^a,b   Kuhn, Lois J ^a,b   Craigmyle, Michael I ^b   Anstead, Michael I ^b   Kanga, Jamshed F ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CYSTIC FIBROSIS; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; SPUTUM CULTURE;

ADOLESCENT; ADULT; CEFTAZIDIME; CEPHALOSPORINS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA;

EID: 0035160682     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.17.1320.34420     Document Type: Article

References (23)

1. Cystic fibrosis
2. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia
3. Management of pulmonary disease in patients with cystic fibrosis
4. Cefepime, the next generation: The reasons and rationale behind its development
5. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients
6. Cefepime: Pharmacokinetics and clinical response in patients with cystic fibrosis
7. Cefepime pharmacokinetics in cystic fibrosis
8. Pharmacokinetics of cefepime in cystic fibrosis patients
9. β-lactamase-mediated resistance to extended spectrum cephalosporins among clinical isolates of Pseudomonas aeruginosa
10. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
11. Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis
12. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis
13. In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum
14. Cefepime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
15. Extended-spectrum-β-lactamases: The role of inhibitors in therapy
16. Evolution and clinical importance of extended-spectrum-β-lactamases
17. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations
18. β-lactam resistance in gram-negative bacteria: Global trends and clinical impact
19. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis
20. Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the Microscan WalkAway System
21. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa
22. Overexpression of the mexC-mexD-opr] efflux operon in nfxB-type multidrug resistant strains of Pseudomonas aeruginosa